Ensuring sustained incentives for pharmaceutical companies to develop medicine for the poor

 

ensuring-sustained-incentives

[6 June, 2016]

The Access to Medicine Foundation report explores the progress made by major pharmaceutical companies in collaborating to innovate products for diseases of poverty, and the success of research & development (R&D) models in incentivizing these contributions. For the past 10 years, the Access to Medicine Foundation has tracked the progress of pharmaceutical engagement in R&D for neglected diseases, they found that models like Product Development Partnerships (PDPs) have been highly successful in creating incentives for pharmaceutical companies to participate in access-friendly R&D.

Ways that PDPs incentivize collaboration:

  • Mitigate risk
  • Pooled resources in priority disease areas
  • Ensuring future access

Incorporating the lessons learned from such models could lead to the creation of a successful system that influences others to drive similar innovations in R&D for neglected populations.

 

 

Download the report: “Ensuring sustained incentives for pharmaceutical companies to develop medicine for the poor”